No Prescription |
 |
 | ||
|
AVIL Generic Pheniramine Maleate |
|
| ||
No Prescription » Prescription Drugs 2 » AVIL Generic Pheniramine Maleate Pheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria. It has relatively strong sedative effects and may sometimes be used off-label as an over-the-counter sleeping pill in a similar manner to other sedating antihistamines such as diphenhydramine.Pheniramine is generally sold in combination with other medications rather than as a stand-alone drug although some formulations are available containing pheniramine by itself. It is sold under the brand name Avil by the pharmaceutical company Aventis. Buy AVIL Generic Pheniramine Maleate and other Prescription Drugs 2 products online at Medstore. 437
About AVIL Generic Pheniramine Maleate: Product Type: Prescription Drugs 2 AVIL ( Generic Pheniramine Maleate ) AVIL (Generic Pheniramine Maleate) Generic Pheniramine Maleate 25mg Tabs 30 (3 x 10) Generic Pheniramine Maleate AVIL
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
